Patent Baristas

The U.S. Federal Trade Commission (FTC) is concerned about the recent use of anti-competitive drug patent deals in light of recent court rulings, which may spur drug companies to step up a practice of paying generic rivals to keep alternatives off the market. The FTC has filed a series of lawsuits challenging patent settlement agreements […]

We’ve been quite busy these days and so posting has been light as a result. Since I have a personal interest in getting my own workload reduced a little, I wanted to pass along that my firm is currently looking to hire on a few IP attorneys. The Position: Looking for a Patent Attorney with […]

The Food and Drug Administration (FDA) announced steps to advance the earliest phases of clinical research in the development of innovative medical treatments. This should make it easier for universities and small drug companies to test promising therapies in humans without having to pay the enormous amounts of expenditures normally required. In guidance documents released […]

A Frost and Sullivan report out says that the expiration of the Polymerase Chain Reaction (PCR) patent (US Patent No. 4,683,202) is setting the stage for growth opportunities for nucleic acid purification and amplification technologies. Companies can now offer tests without developing a novel nucleic acid technology or paying a license fee. The expiration of […]

Bruce MacEwen at Adam Smith, Esq. hosts a wonderful session of Blawg Review this week with a theme of Epiphany. We’re excited about anyone who knows that the 12 days of Christmas start the day after Christmas and end on Epiphany (there is that whole confusion over whether the Twelfth Night is on January 5th […]

One of the items I have trouble keeping up with is reporting on all the excellent law blogs that I come across. One recent addition to my RSS reader is Philip Brooks’ Patent Infringement Updates. This excellent blog provides insight into current events in patent infringement. There’s a whole category devoted to Patent Trolls (Peter […]

Earlier, I asked if anyone could provide insight into the U.S. Patent Office’s proposed rules to limit the number of continuing, CIP and RCE applications that can be filed by patent applicants. Mr. Roy Marsh, a European Patent Attorney in Munich with Hoffmann Eitle, writes: I surmise that the USPTO is envious of EPO success […]

News of patent anarchy are ringing throughout the land citing the troubles with the U.S. Patent and Trademark Office (USPTO) both for its long processing times and cries that it issues too many “unworthy” patents, which fall into the hands of the evil Patent Trolls who hold up legitimate businesses for ransom. While the troll […]